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AbstrAct
Objectives To describe the contemporary trends in the 
use of mechanical circulatory support (MCS) in patients 
with acute myocardial infarction and cardiogenic shock 
(AMICS). To evaluate survival benefit with early application 
of intra- aortic balloon pump (IABP) or Impella CP.
Methods A cohort study of all consecutive patients with 
AMICS undergoing percutaneous coronary intervention 
(PCI) <24 hours of symptom onset (early PCI) in 
southeastern Denmark from 2010 to 2017. A matched 
case–control study comparing 30- day mortality between 
patients receiving early- IABP or early- Impella CP and their 
respective control group. Controls were matched on age, 
left ventricular ejection fraction, arterial lactate, estimated 
glomerular filtration rate and cardiac arrest before PCI. 
Early- IABP/Impella CP was defined as applied before PCI if 
shock developed pre- PCI, or immediately after PCI if shock 
developed during PCI.
Results 903 patients with AMICS undergoing early PCI 
were identified. Use of MCS decreased from 50% in 
2010 to 25% in 2017, p for trend of <0.001. The IABP 
was abandoned in 2012 and replaced mostly by Impella 
CP. Patients receiving MCS in 2013–2017 had more 
compromised haemodynamics compared with patients 
receiving MCS in 2010–2012. 40 patients received early 
IABP, and 40 patients received early Impella CP. Only the 
group receiving early Impella CP was associated with 
lower 30- day mortality compared with their matched 
control group (30- day mortality 40% vs 77.5%, plog- rank 
of<0.001).
Conclusion Use of MCS decreased by 50% from 2010 
to 2017. Patients receiving MCS had more compromised 
haemodynamics in recent years. Early application of 
Impella CP was associated with reduced 30- day mortality 
compared with a matched control group.
IntROduCtIOn
Cardiogenic shock remains a leading cause of 
death following acute myocardial infarction 
with sustained 30- day mortality of approx-
imately 50% for nearly two decades.1 2 Use 
of mechanical circulatory support (MCS) is 
widely debated with no substantial evidence 
supporting its use in patients with acute 
myocardial infarction and cardiogenic shock 
(AMICS). To date, the Intra- aortic Balloon 
Pump (IABP)- SHOCK II trial is the only 
adequately powered randomised controlled 
trial assessing the use of MCS in AMICS, 
and the trial failed to show any prognostic 
benefit with the use of IABP.3 Contemporary 
studies on temporal trends in use of MCS 
in AMICS are limited but generally show a 
Key questions
What is already known about this subject?
 ► There is no randomised controlled trial to support 
the use of mechanical circulatory support (MCS) 
in patients with acute myocardial infarction and 
cardiogenic shock. Little is known about the pa-
tient population receiving MCS in recent years. 
Observational studies show conflicting results but 
generally support implementation of MCS before 
revascularisation.
What does this study add?
 ► The intra- aortic balloon pump (IABP) was replaced 
by Impella CP and, to a lesser extent, venoarterial 
membrane oxygenation following the neutral IABP- 
SHOCK II trial. Fewer patients received MCS after 
IABP- SHOCK II, and patients receiving MCS in re-
cent years had more compromised haemodynamics 
at the time of shock compared with earlier years. 
When taking the timing of shock into consideration, 
not only prepercutaneous coronary intervention 
(PCI) implementation but also immediate post- PCI 
implementation of Impella CP was associated with 
improved outcome compared with a matched con-
trol group.
How might this impact on clinical practice?
 ► This study does not support general use of MCS, 
but if MCS is required, this observational study sup-
ports early use of Impella CP defined as pre- PCI, or 
immediately after PCI if shock develops during the 
procedure.
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Figure 1 Consort diagram of patient selection. Dotted line indicates the cut- off between the trend study and the matching 
study. AMICS, acute myocardial infarction and cardiogenic shock; CCL, cardiac catheterisation laboratory; eGFR, estimated 
glomerular filtration rate; IABP, intra- aortic balloon pump; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary 
intervention.
shift in choice of the device with a decrease in the use of 
IABP and an increase in the use of other devices, namely, 
venoarterial extracorporeal membrane oxygenation (VA- 
ECMO) and transvalvular microaxial flow pumps.4 5 In 
a recent retrospective study, general use of Impella was 
not associated with improved survival compared with 
the IABP.6 However, the percutaneous assist devices 
pooled in the analyses have differing support capabili-
ties and mode of action, and there is increasing evidence 
of a possible timing issue favouring early application of 
MCS .7–12 Therefore, we sought to investigate the use of 
MCS in AMICS and assessed the temporal trends in the 
choice of the device and the patient characteristics of 
those receiving MCS between 2010 and 2017. Further, we 
assessed the survival benefit of early application of IABP 
or Impella CP compared with a matched control group.
MetHOds
study population
All patients fulfilling the criteria for AMICS in the cardiac 
catheterisation laboratory undergoing early percuta-
neous coronary intervention (PCI) (within 24 hours of 
symptom onset) from 2010 to 2017 were identified in the 
RETROSHOCK registry (figure 1). RETROSHOCK is a 
retrospective registry including all consecutive patients 
with an individually validated diagnosis of AMICS, 
admitted to two tertiary cardiac centres that provide 
AMICS care for two- thirds of the Danish population.1 
AMICS was defined as persistent hypotension (systolic 
blood pressure of ≤90 mm Hg for >30 min or use of vaso-
active drugs), end- organ hypoperfusion (altered mental 
status, cold/clammy skin, oliguria or arterial lactate 
≥2.5 mmol/L) and reduced cardiac function, caused by 
an acute myocardial infarction.
Intervention and data collection
The intervention of interest was the use of short- term 
MCS and the device type (IABP, VA- ECMO, Impella 
V.2.5, Impella CP, Impella RP and Impella V.5.0) from 
2010 to 2017. Patient characteristics were obtained at the 
time of shock (ie, in the cardiac catheterisation labora-
tory). Patients were stratified as those who received MCS 
versus those who did not (MCS vs no MCS), in addition 
to the time period (2010–2012 vs 2013–2017). Mean 
arterial pressure was calculated as diastolic blood pres-
sure+0.33×pulse pressure. Estimated glomerular filtra-
tion rate (eGFR) was calculated based on age, gender 
and creatinine on arrival according to the Chronic 
Kidney Disease Epidemiology Collaboration equation.13 
Early MCS application was defined as the initiation of 
IABP/Impella CP before PCI in patients with shock prior 
to the procedure or before leaving the cardiac catheteri-
sation laboratory in patients developing shock during the 
procedure. Timing of shock was determined as pre- PCI 
versus during PCI based on blood pressure, if not speci-
fied in the medical record. Additional MCS was defined 
as the use of more than one device. In the matched study, 
MCS escalation was defined as the transition to a more 
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Figure 2 Temporal trends in the use of MCS from 2010 
to 2017 with different Impella devices delineated. AMICS, 
acute myocardial infarction and cardiogenic shock; IABP: 
intra- aortic balloon pump; MCS, mechanical circulatory 
support; VA- ECMO: venoarterial extracorporeal membrane 
oxygenation.
powerful device (ie, from no device to any MCS, IABP 
to any other MCS, Impella CP to VA- ECMO and Impella 
CP to Impella V.5.0). Patient delay was defined as the 
time from symptom onset to first medical contact. System 
delay was defined as the time from first medical contact 
to insertion of the guiding catheter.
study endpoints
The primary endpoint of this study was 30- day all- cause 
mortality in the intervention group and the matched 
control group. Secondary endpoints were the mode 
of in- hospital death (cardiac, anoxic brain damage or 
multiorgan failure) for the matched cohort and 30- day 
mortality for the entire cohort.
Propensity matching
Use of MCS was considered equal to initiating intensive 
care treatment, along with intubation and vasoactive 
drug infusion. Patients who died in the catheterisation 
laboratory before receiving any form of intensive care 
treatment were considered not to be potential candidates 
for MCS and therefore were excluded from the propen-
sity matched analysis (figure 1). Among the patients from 
2010 to 2012, those receiving an early IABP were matched 
1:1 to their nearest neighbour according to a propensity 
score. Likewise, among the patients from 2013 to 2017, 
those receiving an early Impella CP were matched 1:1 to 
their nearest neighbour according to a propensity score 
(figure 1). The following baseline characteristics were 
used for calculating the propensity score as they have been 
identified as significant risk factors for death in AMICS: 
age (5- year increments), left ventricular ejection fraction 
(LVEF, increments of 5%), arterial lactate at the time 
of shock (≤2.0, 2.1–4.0, 4.1–6.0, 6.1–8.0, 8.1–10.0, 10.1–
12.0 and >12.0 mmol/L), eGFR (grouped as <30, 30–44, 
45–59, 60–89 and ≥90 mL/min/1.73 m2) and resuscita-
tion for cardiac arrest before arrival in the cardiac cath-
eterisation laboratory. We did not identify any residual 
confounding of age, eGFR or lactate as continuous varia-
bles within each respective stratum. Patients randomised 
to Impella CP as part of the ongoing DanGer Shock trial 
(NCT01633502) were excluded from the matched study 
(figure 1).14
statistics
Patient characteristics among those receiving MCS and 
those not receiving MCS were compared both within the 
same period and across different periods (MCS 2010–
2012 vs MCS 2013–2017, no MCS 2010–2012 vs no MCS 
2013–2017, MCS 2010–2012 vs no MCS 2010–2012 and 
MCS 2013–2017 vs no MCS 2013–2017). Student’s t- test 
was used to compare Gaussian data reported as mean 
(SD); Wilcoxon rank- sum test was used to compare non- 
Gaussian data reported as median (Q1, Q3), and χ2 test 
(Fisher’s exact test for sparse data) was used to compare 
proportions reported as number (percentage). Thirty- day 
mortality was estimated using the Kaplan- Meier method, 
and differences between groups were compared using 
the log- rank test. All statistical analyses were performed 
using STATA software V.14.2.
Results
A total of 903 patients presenting to the cardiac cathe-
terisation laboratory with AMICS undergoing early PCI 
between 2010 and 2017 were identified in the registry 
(figure 1). The use of MCS decreased from 50% in 2010 
to 25% in 2017 (figure 2). There was a major shift in the 
choice of MCS since 2012 with a substantial decrease 
in the application of IABP and a concomitant increase 
in the application of Impella CP (figure 2). Given the 
marked change in the choice of device use over time, we 
compared patients receiving MCS before 2012 with those 
receiving MCS after 2012. Patients receiving MCS after 
2012 were younger and had more compromised haemo-
dynamics at the time of shock compared with patients 
receiving MCS before 2012 (table 1 and figure 3). 
Among patients not receiving MCS, more comorbidity 
and slightly more compromised haemodynamics were 
observed in those treated after 2012 compared with 
those treated before 2012. Otherwise, patient character-
istics were balanced across the two eras (table 1). Patients 
not receiving MCS had nearly identical 30- day mortality 
(48%, p=0.95) across eras, but the need for transfusion 
was more frequent in the period before 2012.
We identified 40 patients receiving early IABP and 
40 patients receiving early Impella CP. As all patients 
receiving early IABP/Impella CP survived to intensive 
care treatment, the matched controls were also limited 
to patients receiving intensive care. Values of matching 
covariates and other patient characteristics can be found 
in table 2. The Impella CP group had significantly lower 
30- day mortality compared with the matched control 
group, corresponding to an average number needed to 
treat of 2.7 (30- day mortality 40.0% with early- Impella 
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Figure 3 Box plot for age, systemic systolic blood pressure, 
arterial lactate and LVEF in patients receiving MCS versus 
not receiving MCS in the pre- IABP- SHOCK II (2010–2012) 
and post- IABP- SHOCK II period (2013–2017). IABP, intra- 
aortic balloon pump; LVEF, Left ventricular ejection fraction; 
MCS, mechanical circulatory support.
CP vs 77.5% with control, p<0.001; table 2 and figure 4). 
The improved outcome in the early Impella CP group 
was mainly driven by fewer in- hospital cardiac deaths. 
Although there were numerically fewer deaths in the 
early IABP group compared with the matched control 
group, no statistically significant difference was observed 
(30- day mortality 27.5% with early IABP vs 37.5% with 
control, p=0.35). Following exclusion of patients devel-
oping shock during the procedure, 30- day mortality was 
for early Impella CP versus control: 40.9% vs 79.4%, 
p=0.005, and for early- IABP versus control: 36.0% vs 
41.2%, p=0.61.
dIsCussIOn
The current study demonstrates major changes in the use 
of short- term MCS over the last decade. Patients receiving 
MCS in recent years were younger and had more profound 
cardiogenic shock compared with patients receiving MCS 
in previous years. Interestingly, the choice of MCS device 
changed drastically from IABP to mostly Impella CP after 
the IABP- SHOCK II trial in 2012. Early application of 
Impella CP was associated with lower 30- day mortality 
compared with the matched controls, a trend that was not 
be observed among patients with early application of IABP.
Previous studies from Europe and the USA have demon-
strated similar temporal trends regarding the choice of 
MCS system with decreasing use of IABP and increasing 
use of VA- ECMO, axial pump- related devices and 
Tandem Heart, but not to the same degree as observed in 
the present study.4 15 16 The abandonment of IABP coin-
cides with the published results of the IABP- SHOCK II 
trial, and a similar change in practice has been reported 
from a single- centre in Berlin.17 The present study is 
the first study to delineate between the Impella family 
of devices and to highlight the increased application of 
Impella CP for AMICS in recent years. It should be noted 
that Impella V.2.5 was used in the early years; however, 
its use decreased concomitant with the abandonment 
of IABP following the introduction of Impella CP. Also, 
the initiation of the randomised DanGer Shock trial 
(NCT01633502) involving the Impella CP in 2013 and 
patient recruitment at the two participating institutions 
likely led to increased awareness of Impella CP.14 In addi-
tion, clinicians might have favoured the use of Impella 
CP over Impella V.2.5 given the increased blood flow 
by the Impella CP. Studies reporting on contemporary 
trends on patient populations receiving MCS is scarce, 
and this study shows that patients receiving MCS were 
younger and more haemodynamically compromised in 
recent years (2013–2017) compared with earlier years 
(2010–2012). MCS was applied in ~25% of cases in the 
post- IABP- SHOCK II era compared with ~50% in the 
pre- IABP- SHOCK II era, and was probably restricted to 
patients with more profound shock, explaining the more 
compromised haemodynamics of patients receiving MCS 
in recent years. This concept is further supported by the 
observed increase in mechanical ventilation, vasoactive 
drugs, dialysis and higher 30- day mortality in the MCS 
group from the post- IABP- SHOCK II era versus pre- 
IABP- SHOCK II era. Given the striking differences in the 
patient characteristics of those receiving MCS before and 
after 2012, we exclusively compared the treatment effects 
of early IABP/Impella CP in the two separate time eras.
In agreement with the IABP- SHOCK II trial, early 
application of IABP compared with the matched control 
group was not associated with improved outcome in this 
study.3 Early application of Impella CP was associated with 
improved 30- day mortality corresponding to an average 
number needed to treat of three to avoid one fatality, 
assuming that the intervention drove the difference. 
This contrasts with the recent IMPRESS (MPella versus 
IABP Reduces mortality in STEMI patients treated with 
primary PCI in Severe cardiogenic SHOCK) randomised 
trial of 48 patients, which did not find an overall survival 
benefit of Impella CP compared with IABP.10 In the trial, 
91.7% of patients had cardiac arrest before randomisation 
and might represent an entirely different clinical entity 
compared with the mixed cohort of patients with AMICS. 
The trial did, however, report an absolute risk reduction of 
28% in 30- day mortality when MCS was applied pre- PCI, 
although the numbers were small and difference did not 
reach statistical significance.10 A recent single- centre obser-
vational study found a non- significant absolute 15% lower 
30- day mortality among 62 patients receiving an Impella 
compared with 54 patients receiving an IABP, despite 
the fact that patients receiving Impella had more often 
received out- of- hospital cardiopulmonary resuscitation, 
had lower LVEF and had higher lactate levels at device 
implementation.17 A recent multicentre observational 
study found no survival benefit with general use of Impella 
V.2.5/CP compared with matched patients from the IABP- 
SHOCK II trial cohort, but did report a non- significant 
absolute 10.6% lower 30- day mortality for Impella in the 
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Table 2 Baseline characteristics, in- hospital treatment and outcome for the matched cohort
Early IABP versus control Early Impella CP versus control
Early IABP Control P value Early ImpellaCP Control P value
Number of patients 40 40 40 40
Age (years), mean (SD) 68.8 (11.1) 69.1 (9.9) 0.90 64.5 (10.1) 65.9 (13.3) 0.60
Male sex, n (%) 33 (82.5) 28 (70.0) 0.19 34 (85.5) 29 (72.5) 0.17
BMI (kg/m2), mean (SD) 25.5 (3.7) 26.6 (4.0) 0.28 27.3 24.9 0.01
IHD, n (%) 11 (27.5) 8 (20.5) 0.47 14 (36.8) 17 (43.6) 0.55
Previous MI, n (%) 3 (7.5) 4 (10.3) 0.71 8 (21.1) 8 (20.0) 0.91
Hypertension, n (%) 25 (64.1) 15 (39.5) 0.03 22 (59.5) 23 (59.0) 0.97
Dyslipidaemia, n (%) 11 (28.2) 9 (23.7) 0.65 15 (40.5) 16 (41.0) 0.97
PAD, n (%) 1 (2.5) 2 (5.1) 0.61 2 (5.4) 6 (15.8) 0.26
DM, n (%) 9 (22.5) 6 (15.4) 0.42 7 (18.9) 4 (10.5) 0.35
Previous stroke, n (%) 4 (10.3) 2 (5.1) 0.68 1 (2.7) 1 (2.6) 1.00
COPD, n (%) 1 (2.6) 3 (7.7) 0.62 0 (0.0) 2 (5.3) 0.49
Cardiac arrest, n (%) 9 (22.5) 10 (25.0) 0.79 16 (40.0) 15 (37.5) 0.82
  Time to ROSC (min), median (Q1, Q3) 25 (18, 25) 27 (17, 33) 0.71 23 (15, 75) 27.5 (15, 70) 0.61
STEMI, n (%) 36 (90.0) 38 (95.0) 0.40 27 (67.5) 24 (60.0) 0.49
Patient delay (min), median (Q1, Q3) 75 (20, 256) 108 (24, 205) 0.91 34 (2, 229) 46 (14, 219) 0.46
System delay (min), median (Q1, Q3) 149 (115, 194) 164 (120, 245) 0.41 140 (105, 175) 142 (100, 250) 0.75
Haemodynamics at the time of shock
  Shock before PCI procedure, n (%) 25 (62.5) 34 (85.0) 0.02 22 (55.0) 34 (85.0) 0.003
  Vasoactive drugs, n (%) 27 (67.5) 27 (67.5) 1.00 22 (55.0) 18 (45.0) 0.50
  MAP (mm Hg), mean (SD) 61 (11) 64 (9) 0.20 57 (16) 56 (21) 0.85
  Heart rate (beats/min), mean (SD) 94 (24) 86 (22) 0.15 95 (32) 77 (33) 0.02
  LVEF (%), median (Q1, Q3) 27.5 (20, 40) 30 (22.5, 37.5) 0.76 15 (10, 25) 15 (10, 25) 0.77
  Lactate (mmol/L), median (Q1, Q3) 3.5 (1.8, 5.7) 3.2 (2.0, 5.9) 0.92 8.5 (4.5, 11.7) 8.3 (3.7, 13.4) 0.72
eGFR (mL/min/1.73 m2), mean (SD) 62 (24) 60 (21) 0.67 63 (21) 60 (19) 0.61
In- hospital management and outcome
  30- day mortality, n (%) 11 (27.5) 15 (37.5) 0.32 16 (40.0) 31 (77.5) <0.001
  Cause of in- hospital death, n (%)
  Cardiac 8 (20.0) 7 (17.5) 0.78 7 (17.5) 18 (45.0) 0.008
  Multiorgan failure 1 (2.5) 3 (7.5) 1.00 6 (15.0) 5 (12.5) 1.00
  Anoxic brain injury 1 (2.5) 2 (5.0) 1.00 2 (5.0) 3 (7.5) 1.00
  Other, n (%) 1 (2.5) 2 (5.0) 1.00 1 (2.5) 2 (5.0) 1.00
  Mechanical ventilation, n (%) 24 (60.0) 27 (67.5) 0.49 36 (90.0) 35 (87.5) 1.00
  Vasoactive drug use overall, n (%) 36 (90.0) 40 (100) 0.12 39 (97.5) 39 (97.5) 1.00
  Escalating MCS, n (%) 2 (5.0) 19 (47.5) <0.001 5 (12.5) 12 (30.0) 0.10
  Use of VA- ECMO 0 (0.0) 0 (0.0) 1.00 4 (10.0) 7 (17.5) 0.35
  Renal replacement therapy for AKI 8 (20.5) 8 (21.0) 0.95 19 (48.7) 11 (28.2) 0.10
  Limb ischaemia 1 (2.6) 1 (2.5) 1.00 4 (10.0) 3 (7.5) 1.00
AKI, acute kidney injury; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, 
estimated glomerular filtration rate; IABP, intra- aortic balloon pump; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; 
MAP, mean arterial pressure; MCS, mechanical circulatory support; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, 
percutaneous coronary intervention; ROSC, return of spontaneous circulation; STEMI, ST elevation myocardial infarction; VA- ECMO, 
venoarterial extracorporeal membrane oxygenation.
pre- PCI subgroup analysis.6 Other observational studies 
have compared the effect of Impella application pre- PCI 
versus post- PCI, and the results favour pre- PCI Impella.7 8 
These studies may suffer from confounding by indication, 
as patients in whom PCI fails to stabilise haemodynamics 
and receive Impella post- PCI may have a worse outcome 
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Figure 4 Kaplan- Meier curves of 30- day mortality 
with early- Impella CP versus propensity score- matched 
controls and early- IABP versus propensity score- matched 
controls. Propensity score was calculated based on age, 
left ventricular ejection fraction, lactate levels, estimated 
glomerular filtration rate and cardiac arrest before arrival 
to the cardiac catheterisation laboratory. IABP: intra- aortic 
balloon pump.
compared with those receiving Impella pre- PCI. Experi-
mental animal studies have demonstrated that deploying 
an unloading MCS system prior to reperfusion has been 
demonstrated to reduce infarct size in various species, and 
that a strategy of Impella CP and norepinephrine improved 
end- organ perfusion without increasing myocardial work-
load in a large porcine model of profound cardiogenic 
shock.18–21 In the present study, the improved survival 
effect of early Impella CP was primarily driven by fewer 
in- hospital cardiac deaths, supporting the association of 
improved outcome with early left ventricular unloading. 
However, no definite conclusions can be drawn from this 
observational study that at the best should be considered 
hypothesis generating.
lIMItatIOns
The clear- cut change in choice of device (primarily IABP 
from 2010 to 2012, and primarily Impella CP from 2013 to 
2017) caused no overlap in time when the two devices were 
at disposal simultaneously, and given the striking difference 
in the patient population receiving MCS across the two time 
periods, we compared early use of IABP and early use of 
Impella CP to their nearest neighbour control within their 
respective time periods, instead of comparing early IABP to 
early Impella CP. In the absence of randomised controlled 
trials, the propensity score is a method to obtain balance 
between groups in the search for causal inference and is 
defined as the probability of receiving treatment given 
the observed baseline covariates.22 One- to- one nearest- 
neighbour matching is superior to the classic regression 
analysis in reducing bias, especially if covariates are poorly 
balanced between groups.23 Despite propensity matching, 
the present study carries the risk of confounding by indi-
cation, selection bias and bias due to unmatched and 
unobserved covariates. We chose to exclude patients dying 
in the catheterisation laboratory before receiving inten-
sive care treatment, which may have underestimated the 
effect of MCS. However, matched controls in such a setting 
would have included patients where MCS was abandoned 
due to futility, which would have led to an overestimation 
of the MCS effect. We speculate that additional selection 
bias might have occurred in the early- IABP group, given 
the lower rate of in- hospital deaths due to multiorgan 
failure since the IABP does not improve end- organ perfu-
sion or risk of multiorgan dysfunction as demonstrated in 
an experimental porcine model of moderate acute heart 
failure and IABP- SHOCK I and II trials.3 24 25 The possibility 
of additional selection bias in the early- Impella CP versus 
matched control group cannot be excluded as well. Over-
matching is a potential limitation as we cannot exclude the 
possibility of assessment of LVEF/measurement of arte-
rial lactate and creatinine having occurred after initiation 
of early IABP/Impella CP in some cases. The probability 
of undermatching is less likely as matching variable strata 
were narrow and no residual confounding was observed 
of the continuous variables within their respective strata. 
Additional overestimation and underestimation of treat-
ment effects could also have occurred, and the influence 
of a learning curve with the use of Impella CP cannot be 
excluded. The number of patients who received an early 
device was limited, and this study does not replace the need 
for a randomised controlled trial. We do, however, find 
it encouraging that 30- day mortality improved with early- 
Impella CP versus matched control group, and not with 
early- IABP versus matched control group, using the same 
matching procedure.
COnClusIOn
In this historical follow- up study of patients with AMICS 
undergoing PCI within 24 hours of symptom onset in 
southeastern Denmark, the use of MCS decreased by 
50% and a shift from IABP to mostly Impella CP occurred 
following the IABP- SHOCK II trial. Patients receiving 
MCS after 2012 were younger and presented with more 
compromised haemodynamics compared with patients 
receiving MCS prior to 2012. When compared with 
their respective temporal matched control group, early 
application of Impella CP was associated with improved 
survival, while early application of IABP was not.
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